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Abstract 
Diabetes is a major global health threat to the human health as the prevalence has rapidly increased over the past four decades. The costs of 
diabetes include both direct costs from medical care as well as indirect costs incurred through loss of productivity or earnings, both of which 
are important contributors to the global economic burden. Global trend with focus on green medicine serve as an important safe & alternative 
cost effective therapy as compared to allopathic medicine. Plants have their chemical compounds which demonstrate alternative and safe 
effects on diabetes mellitus. Most of plants contain glycosides, alkaloids, terpenoids, flavonoids, carotenoids, etc., that are frequently implicated 
as having antidiabetic effect. Herbalism is becoming focusing point due to research on herbs and their use in treatment of diabetes and its 
prevention The scientific study of traditional medicines, concerned medicinal plants are thus of great importance.  
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Introduction 
The term Diabetes was first coined by Apollonius of 
Memphis around 250 B.C, which literally meant “to go 
through” or siphon as the disease drained more fluid than a 
person could consume. Diabetes is a chronic disorder of 
carbohydrate, fat and protein metabolism characterized by 
increased fasting and post prandial blood sugar level, which 
causes congenital (type I insulin-dependent) or acquired 
(type II noninsulin-dependent) diabetes mellitus.1 Diabetes 
contribute 1.3 million deaths globally, but it is a major risk 
factor for other causes of death also and is therefore high 
attributable economic burden of disability as the synthetic 
drugs used for the treatment cause serious side-effects. 
Herbal drugs introduced with modern technology can lower 
economic burden besides being having high therapeutic 
index value. 
The global burden of Diabetes Mellitus 
Globally, an estimated 422 million adults were living with 
diabetes in 2014, compared to 108 million in 1980. The 
global prevalence (age-standardized) of diabetes has nearly 
doubled since 1980, rising from 4.7% to 8.5% in the adult 
population. In 1994, the International Diabetes Federation 
(IDF) Directory included type I and type II diabetes 
estimates supplied by member nations. Using these data, IDF 
estimated that over 100 million people worldwide had 
diabetes.WHO also produced a report using epidemiological 
information and estimated the global burden at 135 million 
in 1995, with the number reaching 299 million by the year 
2025.2 In the 2006 3rd edition of the Diabetes Atlas the 
estimates were of 246 million people worldwide with 
diabetes for 2007, and an anticipated 380 million for 
2025. In 2000, India (31.7 million) topped the world with 
the highest number of people with diabetes mellitus 
followed by China (20.8 million) with the United States (17.7 
million) in second and third place respectively.3The National 
Urban Survey conducted across the metropolitan cities of 
India revealed percentage of population affected by 
diabetes:11.7 per cent in Kolkata (Eastern India), 6.1 per 
cent in Kashmir Valley (Northern India)4 11.6 per cent in 
New Delhi (Northern India), and 9.3 per cent in West India 
(Mumbai) compared with (13.5 per cent in Chennai (South 
India), 16.6 per cent in Hyderabad (south India), and 12.4 
per cent Bangalore (South India).  
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Classification  
The etiologic classifications of diabetes mellitus are listed below. Adapted from WHO and ADA5,6  
Table 1: Etiological Classification of Diabetes 
I. Type 1 Diabetes mellitus 
 A. Autoimmune 
 B. Idiopathic  
II. Type 2 Diabetes mellitus  
Ranges from relative insulin deficiency to 
disorders of insulin secretion and insulin 
resistance  
III. Other specific types of diabetes mellitus  
A. Genetic defects in β-cell function  
1. Chromosome 12, HNF-1α (MODY 3) 
2. Chromosome 7, glycosidase (MODY 2)  
3. Chromosome 20, HNF-4α (MODY 1) 
 4. Mitochondrial DNA  
5. Monogenic diabetes 
B. Genetic defects in insulin action 
1. Type A insulin resistance  
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
 4. Lipotrophic diabetes  
C. Disease of the exocrine pancreas 
1. Pancreatitis   
2. Pancreatectomy/trauma 
3. Neoplasia  
4. Cystic fibrosis 
5. Hemochromatosis 
6. Fibrocalcific pancreatopathy 
D. Endocrinopathies  
1. Acromegaly 
2. Cushing syndrome 
3. Glucagonoma  
4. Pheochromocytoma 
5. Hyperthyroidism  
6. Somatostatinoma  
7. Aldosteronoma 
i.Pharmacologically or chemically induced 
1. Vacor 
 2. Pentamidine 
 
 
 
3. Nicotinic acid 
4. Glucocorticoids  
5. Thyroid hormones  
6. Diazoxide  
7. β-adrenergic agonists 
8. Tiazides  
9. Dilantin 
10. α interferon  
ii. Infections 
1. Congenital rubeola  
2. Cytomegalovirus  
iii. Infrequent forms of autoimmune diabetes  
1. Stiff-man syndrome 
2. Antibodies against insulin receptors  
iv. Other syndromes occasionally associated with 
diabetes 
1. Down syndrome 
2. Klinefelter syndrome  
3. Turner syndrome 
4. Wolfram syndrome  
5. Friedreich ataxia 
6. Huntington’s chorea  
7. Lawrence-Moon-Biedel syndrome 
8. Myotonic dystrophy 
9. Porphyria  
10. Prader-Willi syndrome  
IV. Gestational diabetes mellitus 
 Occurs in mostly in women during gestation. 
 
 Type I diabetes mellitus  
Type I diabetes mellitus (juvenile diabetes) is characterized 
by beta cell destruction caused by an autoimmune process, 
usually leading to absolute insulin deficiency7 Type I is 
usually characterized by the presence of anti–glutamic acid 
decarboxylase, islet cell or insulin antibodies which identify 
the autoimmune processes that lead to beta cell destruction. 
Eventually, all type I diabetic patients will require insulin 
therapy to maintain normoglycemia. 
 Type II diabetes mellitus 
Type II diabetes mellitus is characterized by hyperglycemia, 
insulin resistance, and relative impairment in insulin 
secretion. Most individuals with Type II diabetes exhibit 
intra-abdominal (visceral) obesity, which is closely related to 
the presence of insulin resistance8. In addition, hypertension 
and dyslipidemia (high triglyceride and low HDL-cholesterol 
levels; postprandial hyperlipidemia) often are present in 
these individuals. This is the most common form of diabetes 
mellitus and is highly associated with a family history of 
diabetes, older age, obesity and lack of exercise. It is more 
common in women, especially women with a history of 
gestational diabetes, and in Blacks, Hispanics and Native 
Americans. 
Clinical features of Type I and type II diabetes 
a) Clinical features of Type I Diabetes 
Some of the symptoms include weight, polyurea, polydipsia, 
polyphagia, constipation fatigue, cramps, blurred vision, and 
candidiasis9. Long lasting type I DM patients may be 
susceptible to microvascular complications.10and 
macrovascular disease (coronary artery, heart, and 
peripheral vascular diseases)11 
b) Clinical features of Type II diabetes 
Most cases are diagnosed because of complications or 
incidentally. Carries a high risk of large vessel 
atherosclerosis commonly associated with hypertension, 
hyperlipidaemia and obesity. Most patients with type II 
diabetes die from cardiovascular complications and end 
stage renal disease. Geographical variation can contribute in 
the magnitude of the problems and to overall morbidity and 
mortality12,13  
Other speciﬁc types of diabetes 
 Genetic defects of the β-cell.  
Several forms of diabetes are associated with monogenetic 
defects in β-cell function. These forms of diabetes are 
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frequently characterized by onset of hyperglycemia at an 
early age (generally before age 25 years). They are referred 
to as maturity onset diabetes of the young (MODY) and are 
characterized by impaired insulin secretion with minimal or 
no defects in insulin action. 14 
 Diseases of the Exocrine Pancreas 
Any process that diffusely injures the pancreas can cause 
diabetes. Acquired processes include pancreatitis, trauma, 
infection, pancreatectomy, and pancreatic carcinoma  
 Endocrinopathies 
Several hormones (e.g., growth hormone, cortisol, glucagon, 
epinephrine) antagonize insulin action. Excess amounts of 
these hormones (e.g., acromegaly, Cushing’s syndrome, 
glucagonoma, pheochromocytoma, respectively) can cause 
diabetes. This generally occurs in individuals with 
preexisting defects in insulin secretion, and hyperglycemia 
typically resolves when the hormone excess is resolved. 
Drug- or Chemical-Induced Diabetes 
Many drugs can impair insulin secretion. These drugs may 
not cause diabetes by themselves, but they may precipitate 
diabetes in individuals with insulin resistance. In such cases, 
the classiﬁcation is unclear because the sequence or relative 
importance of β-cell dysfunction and insulin resistance is 
unknown. Certain toxins such as Vacor (a rat poison) and 
intravenous pentamidine can permanently destroy 
pancreatic -cells. Such drug reactions fortunately are rare. 
There are also many drugs and hormones that can impair 
insulin action. Examples include nicotinic acid and 
glucocorticoids. 
 Infections 
Certain viruses have been associated with β-cell destruction. 
Diabetes occurs in patients with congenital rubella, although 
most of these patients have HLA and immune markers 
characteristic of type I diabetes. In addition, coxsackievirus 
B, cytomegalovirus, adenovirus, and mumps have been 
implicated in inducing certain cases of the disease.15,16 
 Uncommon Forms of Immune-Mediated Diabetes 
 Other Genetic Syndromes 
Many genetic syndromes are accompanied by an increased 
incidence of diabetes mellitus. These include the 
chromosomal abnormalities of Down’s syndrome, 
Klinefelter’s syndrome, and Turner’s syndrome. Wolfram’s 
syndrome is an autosomal recessive disorder characterized 
by insulin-deﬁcient diabetes and the absence of -cells at 
autopsy.  
Gestational Diabetes Mellitus (GDM)  
Pathogenesis of Diabetes 
a) Pathogenesis of Type I Diabetes 
Type I DM is the culmination of lymphocytic infiltration and 
destruction of insulin-secreting beta cells of the islets of 
Langerhans in the pancreas. As beta-cell mass declines, 
insulin secretion decreases until the available insulin no 
longer is adequate to maintain normal blood glucose levels. 
After 80-90% of the β-cells cells are destroyed, 
hyperglycemia develops and Diabetes may be diagnosed. 
Currently, autoimmunity is considered the major factor in 
the pathophysiology of type I DM.  
b) Pathogenesis of Type II Diabetes 
Type II Diabetes is characterized by a combination of 
peripheral insulin resistance and inadequate insulin 
secretion by pancreatic beta cells. Insulin resistance, which 
has been attributed to elevated levels of free fatty acids and 
proinflammatory cytokines in plasma, leads to decreased 
glucose transport into muscle cells, elevated hepatic glucose 
production, and increased breakdown of fat. A role of excess 
glucagon cannot be overestimated; indeed, type II is an islet 
paracrinopathy in which the reciprocal relationship between 
the glucagon-secreting α cell and the insulin-beta cells lost, 
leading to hyperglucagonemia and hence the consequent 
hyperglycemia. 
 Complications of Diabetes Mellitus 
1- Acute complications 
 Hypoglycemia 
 Hyperglycemic crises  
 Diabetes Ketoacidosis (DKA) 
 Hyperglycemic hyperosmolar state (HHS)  
2- Chronic Complications 
a)  Micro vascular complications  
 Diabetic retinopathy 
 Diabetic nephropathy   
 Diabetic neuropathy 
b)  Macrovascular disease  
3.  Other Complications and Associated Conditions  
 Impaired growth and development        
 Associated autoimmune conditions like 
Hypothyroidism, Hyperthyroidism, Celiac disease, 
Vitiligo, Primary adrenal insufficiency (Addison’s 
disease)       
 Lipodystrophy (lipoatrophy and lipohypertrophy)      
 Necrobiosis lipoidica diabeticorum       
 Non-alcoholic fatty liver disease      
 Infections seen in patients with diabetes      
 Limited joint mobility     
Management of Diabetes 
The goal of diabetes management is to keep blood glucose 
levels as close to normal as safely possible. Since diabetes 
may greatly increase risk for heart disease and peripheral 
artery disease, measures to control blood pressure and 
cholesterol levels are an essential part of diabetes treatment 
as well. 
Management of Type II Diabetes 
a) Non-pharmacological Therapy 
Non-pharmacological measures including diet, exercise and 
stress alleviation are as important interventions for the 
management of diabetes.  
 Medical Nutrition Therapy (MNT) 
A proper diet is important component of therapy in all 
patients with diabetes. In patients with Type II DM 
recommendations for caloric distribution is as follows: 55-
60% energy from carbohydrate, 10-15% from protein and 
20-25% from fats. This dietary distribution is also indicated 
in patients with type I diabetes on intensive insulin regimens 
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in whom near-normoglycemic control is less achievable on 
diets higher in carbohydrate content. 
 Dietary Fiber 
Fibers such as cellulose or hemicelluloses, as found in bran, 
termed as insoluble fibers increases intestinal transit time 
and may have beneficial effects on colonic function. Soluble 
fibers such as gums and pectin’s, as found in beans, oatmeal, 
or apple skin, tend to decrease gastric and intestinal transit 
slowing glucose absorption thus decreasing hyperglycemia.  
 Artificial Sweeteners 
The nonnutritive sweetener saccharin is widely used as a 
sugar substitute. Aspartame may prove to be the safest 
sweetener for use in diabetics which is180 times as sweet as 
sucrose. A major limitation is its heat labiality, which 
precludes its use in baking or cooking. These should be used 
in moderation. 
 Fruits 
Fruits (whole) should be taken in moderation. However, very 
sweet fruits and fruit juices can be avoided. 
 Alcohol 
Alcohol intake is best avoided and if used must be in 
moderation as it may worsen the dyslipidemia, neuropathy 
and glycemic control. 
 Common Salt 
Up to 6 gms /day of are permitted. Restrict pickles, papad, 
chatni and salty processed foods.  
 Physical Activity 
In Type II DM exercise programme to achieve weight 
reduction and calorie counting is central to the management. 
The best form of exercise is a stepwise increase in aerobic 
exercises. All diabetics need to be evaluated to rule out any 
contraindication like proliferative diabetic retinopathy, 
autonomic neuropathy etc. before any exercise programme. 
Brisk walking for 30-60 minutes or equivalent should be 
enforced regularly. Yoga, a traditional Indian system, has 
been demonstrated to have beneficial effect in diabetes. 
Some aspects of Yoga like, Asanas (involving postures), 
Pranayama (involving breath), Dhayana (meditation) and 
Bhavana (visualization) are beneficial but need to be learnt 
under expert guidance.17 
b) Pharmacological Therapy 
1. Drugs that primarily stimulate insulin secretion, known 
as insulin secretagogues.  
2. Drugs that sensitize tissues (primarily liver and 
adipose tissue) to the action of insulin named as insulin 
sensitizers. 
3. There are drugs that principally affect absorption of 
glucose therefore retarding the Postprandial 
hyperglycemia. 
 Insulin Secretogogues 
 Sulfonylureas 
The proposed mechanisms of action of the sulfonylureas 
include:  
a) augmentation of insulin release from pancreatic β cells 
and 
b) potentiating of insulin action on its target cells. 
 
 Meglitinides 
This is another class of secretogauges. They are similar to 
sulfonylureas in their mechanism of action but lack the 
sulfonic acid-urea moiety products. Repaglinide is given 
three times a day 15 minutes before each meal (max. dose.of 
16 mg/day); nateglinide is given 60 mg three times a day. 
The drug may be useful for postprandial hyperglycemia, 
elderly and in patients with renal impairment.  There are less 
chances of hypoglycemia and useful in patients who have an 
inconsistent daily schedule with long gaps between meals18 
Several novel insulin secretagogues have been reported to 
act by closing the K-ATP channels. The meglitinide derivative 
mitiglinide (KAD -1229) appears to bind at the benzamide 
site on SUR113. 
 Insulin Sensitizers 
 Biguanides 
Phenformin has been discontinued because of its association 
with the development of lactic acidosis in patients with 
coexisting liver or kidney disease. Metformin (1, 1-
dimethylbiguanide hydrochloride) was introduced in France 
in 1957 as an oral agent for therapy of Type II DM, either 
alone or in combination with sulfonylureas. In 1995 FDA 
approved its use in the United States but has been used in 
most of the countries, including India, for over 4 decades. 
The exact mechanism of action of metformin is not clear but 
it may reduce hepatic gluconeogenesis, slow down 
gastrointestinal absorption of glucose and increase uptake 
by skeletal muscle. It can be used as monotherapy, an adjunct 
to diet, sulfonylurea’s, thiazolidinediones or insulin. 
Metformin is relatively contraindicated in patients with 
cardiorespiratory insufficiency, impaired renal function, any 
state likely to be associated with tissue hypoxia, general 
anesthesia, use of radiographic contrast media, and age of 70 
years. Common side effects of metformin are gastrointestinal 
symptoms (anorexia nausea vomiting, abdominal discomfort, 
diarrhea. Lactic acidosis, though uncommon with metformin 
in contrast to phenformin, is reported in cases with 
associated risk factors such as renal, hepatic, or 
cardiorespiratory insufficiency, alcoholism and advanced age 
14.  
 Thiazolidinediones 
These agents sensitize peripheral tissues to insulin by 
binding to a nuclear receptor called peroxisome 
proliferators-activated receptor-gamma (PPARg). Other 
effects including, increased glucose transporter expression 
(GLUT I and GLUT 4), decreased free fatty acid levels, 
decreased hepatic glucose output, and increased 
differentiation of preadipocytes into adipocytes have also 
been observed. Troglitazone, was withdrawn because it 
caused acute liver failure. Rosiglitazone and pioglitazone are 
used as monotherapy, or in combination with sulfonylurea’s, 
metformin, and insulin. Common side effect is weight gain, 
especially when the drug is combined with a sulfonylurea or 
with insulin. The dosage of rosiglitazone is 4-8 mg daily and 
of pioglitazone 15-45 mg daily. Recently Roziglitazone is 
withdrawn from India and most other countries due to 
cardiac safety. 
 Inhibitors of Intestinal Carbohydrate Absorption 
 Alpha-Glucosidase Inhibitors 
Acarbose and miglitol are competitive inhibitors of intestinal 
brush border alpha-glucosidases, thus delaying the 
absorption of carbohydrates and reduce postprandial 
glycemic excursion. Both of these agents are potent 
inhibitors of glucoamylase, amylase, and sucrase. They are 
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less effective on isomaltase and are ineffective on trehalase 
and lactase. The common adverse effect is flatulence. 
Troublesome diarrhea seen in 3% of cases. The starting dose 
of acarbose is 25 mg twice daily and can be gradually 
increased to 100 mg three times daily. A slight rise in hepatic 
aminotransferases has been noted in clinical trials (5% 
versus 2% in placebo controls, and particularly with doses 
greater than 300 mg/d). Miglitol is structurally similar to 
glucose, is absorbable and is similar to acarbose in terms of 
its clinical effects. Miglitol should not be used in renal failure 
since its clearance is impaired in this setting.19 
 Incretin Mimetics 
Insulin has been shown to be released more effectively 
through an oral glucose load than intravenously and this is 
known as the incretin effect.  
Dipeptidyl Peptidase Inhibitors 
This class of drugs act slowing breakdown of GLP-1 
analogues. These agents works by enhancing the sensitivity 
of β cells to glucose, which causes enhanced glucose 
dependent insulin secretion. Many studies using sitagliptin 
and vildagliptin alone or in combination have shown a 
positive effect on values of HbA1c.  
Phosphodiesterase Inhibitors and other and Approaches  
The β - cell expresses several phosphodiesterases (PDEs) 
that degrade cAMP and so reduce insulin release. Transient 
inhibition of these enzymes in   β- cells, especially isoform 
PDE-3B, which exerts most influence on glucose induced 
insulin secretion, could be a possible intervention.20  
Peroxisome Proliferator Activated Receptor Agonists 
Current, thiazolidinediones (pioglitazone and rosiglitazone) 
exert their “insulin sensitizing” effects largely by stimulating 
the peroxisome proliferator activated receptor γ. Stimulation 
of these receptor increase adipogenesis, enhance insulin 
sensitivity. Additional thiazolidinediones that stimulate 
PPAR γ are being developed (e.g. rivoglitazone), and non 
thazolidinedione PPAR γ agonists have been reported.  
Other Potentiators of Insulin Action 
 Bromocriptine 
The dopamine D2 receptor agonist bromocriptine used in the 
treatment of Parkinson disease, galactorrhea and 
prolactinomas, has long been known to improve insulin 
sensitivity and glycemic control in Type II DM. 
Bromocriptine as monotherapy or an adjunct to other 
antidiabetic agents for up to 1 year has reduced HbA1c by 0.5 
– 1.2%, reduced triglyceride, reduced some cardiovascular 
events, has not caused serious hypoglycaemia.21  
 Lipoic Acid, Isoferulic Acid and Angiotensin-
Converting Enzyme Inhibitors 
The antioxidant α - lipoic acid, used in some countries to 
treat diabetic neuropathy, increases insulin sensitivity and 
improves glycemic control. Isoferulic acid increases 
expression of GLUT-4 and decreases gluconeogenesis. 
Modest improvements of insulin sensitivity have been seen 
during treatment with angiotensin converting enzyme (ACE) 
inhibitors, possibly because of improved hemodynamics 
resulting from increased bradykinin.22Anti-obesity agents: 
Several centrally acting appetite suppressing and satiety 
inducing anti - obesity agents also exert peripheral effects 
that improve some actions of insulin and assist glycemic 
control in overweight patients. Sibutramine and 
Rimonabant: has already been withdrawn because of side 
effects.23 
Sodium Glucose Cotransporter 2 Inhibitors 
Glucose is filtered through the renal glomeruli and all that 
has been filtered is reabsorbed in the proximal tubules. 
Reabsorption is mediated mostly via the sodium glucose co-
transporter 2 (SGLT2) systems. Thus, specific inhibition of 
these transporters reduces hyperglycemia by elimination of 
excess glucose in the urine. Selective inhibitors of SGLT2 
have been developed recently.24  Possible adverse effects of 
osmotic diuresis during SGLT2 inhibition include risk of 
dehydration and electrolyte imbalance, as well as infection in 
the urinary tract and urogenital region.  
Sirtuins 
Sirtuins comprise a group of seven enzymes that are 
nicotinamide adenine-dinucleotide (NAD)-dependent-
histone deacetylases and /or ADP ribosyltransferases. 
Sirtuin SIRT1 is widely expressed in mammalian tissues 
including liver, muscle and fat, and appears to promote 
mitochondrial biogenesis and activity in some tissues, 
increasing thermogenesis and reducing susceptibility to 
weight gain, diabetes and cardiovascular disease. SIRT1 in 
pancreatic β- cells may also facilitate insulin secretion. 
Several small molecule activators of SIRT1 have been studied 
in animal models.25 
Management of type I Diabetes Mellitus 
Insulin 
Insulin is the only therapy available for patients with type I 
diabetes. Insulin replacement in patients with type I diabetes 
has been less than optimal because it is not possible to 
completely reproduce the normal physiologic pattern of 
insulin secretion into the portal vein.  
Four principal types of insulin are available: 
(a) Ultra short-acting insulin, with very rapid onset and 
short duration of action;  
(b) Short-acting insulin, with rapid onset of action;  
(c) Intermediate-acting insulin; and 
(d) Long-acting insulin, with slow onset of action. 
Ultra-short-acting and short-acting insulins are dispensed as 
clear solutions at neutral pH. All other commercial insulins 
have been specifically modified to obtain more prolonged 
action. 
 Rapid and long-acting insulin analogs: Rapid-acting insulin 
analogs, such as insulin aspart, insulin glulisine and insulin 
lispro have a faster onset of action, sharper and earlier peak 
activity and more rapid return to baseline levels than regular 
human insulin. Given before the evening meal, large doses of 
regular insulin increase the risk of nocturnal hypoglycemia. 
These problems are reduced with rapid-acting insulin 
analogs.26Long-acting insulin analogs, detemir and glargine, 
the first soluble insulin analogs have a prolonged time action 
profile. Bolus/basal therapy that combines premeal aspart or 
lispro with glargine or detemir insulin has emerged as the 
‘gold standard’ for intensive injection therapy provided 
through multiple daily injections (MDI) in adults withType I 
DM.27  
Methods of Insulin Administration 
A. Insulin Syringes and Needles:  
B. Pen devices:  
C. Sites for Injection: Any part of the body covered by loose 
skin can be used as an injection site, including the abdomen, 
thighs, upper arms, flanks, and upper outer quadrants of the 
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buttocks. Exercise facilitates insulin absorption when the 
injection site is adjacent to the exercising muscle.  
New and Improved Insulin Delivery Devices 
 Advances in diabetes technology have helped to improve the 
outcomes of management of Type I DM in last three decades. 
 Intranasal 
 Insulin Pumps and Continuous Subcutaneous 
Insulin Infusion  
 Continuous Glucose Monitoring (CGM) Systems 
 Other Modes of Therapy in Type I DM. 
 Amylin Analogues 
 Pancreatic and Islet Transplantation 
 Immunotherapy 
 Novel Drugs 
1. Alogliptin (Nesina, Kazano, Oseni): Approved January 
2013 
On January 25, 2013, Takeda Pharmaceutical received 
approval for alogliptin, a type II diabetes drug. Alogliptin is a 
dipeptidyl peptidase IV (DPP-4) inhibitor that stimulates the 
release of insulin by preventing GLP-1, a compound that 
helps to lower blood sugar, from breaking down. 
2. Invokana: Approved March 2013 
Invokana (canagliflozain) from Janssen Pharmaceuticals is 
the first in a new class of type II diabetes drugs that was FDA 
approved in March 2013. Invokana is a sodium-glucose co-
transporter 2 (SGLT2) inhibitor that blocks the 
reabsorption of glucose (blood sugar) by the kidneys and 
increases glucose excretion in the urine. This oral diabetes 
treatment is indicated to improve blood sugar control in 
conjunction with diet and exercise in patients with type II 
diabetes. 
3. Farxiga: Approved January 2014 
In January 2014, the U.S. Food and Drug Administration 
(FDA) approved Farxiga (dapagliflozin) tablets to improve 
glycemic (sugar) control, along with diet and exercise, in 
adults with type II diabetes. Like Invokana, Farxiga is also a 
sodium-glucose co-transporter 2 (SGLT2) inhibitor. Farxiga’s 
effectiveness was shown in 16 clinical trials involving more 
than 9,400 patients.  
4. Tanzeum: Approved April 2014 
GSK’s Tanzeum (albiglutide), approved in April 2014, is 
classified as a glucagon-like peptide-1 (GLP-1) receptor 
agonist. GLP-1 is a hormone that helps normalize blood 
sugar levels in patients with type II diabetes. Tanzeum binds 
to GLP-1 to stimulate the release of glucose-dependent 
insulin, while blocking release of sugar-boosting glucagon 
from the pancreas. Tanzeum is given by subcutaneous 
(under the skin) injection, and, as with most diabetes 
treatments, is to be used alongside diet and exercise. The 
safety and effectiveness of Tanzeum was shown in eight 
clinical trials involving over 2,000 participants with type II 
diabetes.  
5. Jardiance: Approved May 2014 
In May 2014, the FDA approved the third SGLT blocker to 
enter the U.S. market, Jardiance (empagliflozin). In seven 
type II diabetes clinical trials with about 4,500 people, 
Boehringer Ingelheim’s Jardiance improved hemoglobin A1c 
levels compared to placebo. Jardiance can also be used with 
metformin, sulfonylureas, pioglitazone, and insulin. 
6. Afrezza: Approved June 2014 
Afrezza (insulin human) Inhalation Powder was approved by 
the FDA in June 2014. Afrezza is an ultra-rapid-acting inhaled 
insulin that is administered with meals to improve glycemic 
control in adult diabetics. In clinical trials, Afrezza was 
evaluated in 24-week studies in both type I and type II 
diabetic patients. In 1,026 type I patients also using long-
acting insulin, Afrezza effectiveness to lower blood sugar 
(A1c) provided less A1c reduction than insulin aspart (an 
injectable fast-acting insulin), and the difference was 
statistically significant. In 1991 type II patients also using 
oral antidiabetic agents, inhaled Afrezza did significantly 
lower A1c compared to a placebo group (also using oral 
antidiabetics) in a 24-week study. Afrezza, because it is 
inhaled and not injected, may cause the serious side effect of 
bronchospasm in patients with asthma or chronic 
obstructive pulmonary disease (COPD), and should not be 
used in these patients. The most common adverse reactions 
associated with Afrezza in clinical trials were hypoglycemia 
(low blood sugar), cough, and throat pain or irritation. 
Herbs used in the treatment of Diabetes 
It has been estimated that more than 400 traditional plants 
or plant-derived products have been used for the 
management of type II diabetes across geographically and 
about 800 plants have anti-diabetic potential. Plants have 
their chemical compounds which demonstrate alternative 
and safe effects on diabetes mellitus. Most of plants contain 
glycosides, alkaloids, terpenoids, flavonoids, carotenoids, 
etc., that are frequently implicated as having antidiabetic 
effect. Herbalism is becoming focusing point due to research 
on herbs and their use in treatment of diabetes and its 
prevention The scientific study of traditional medicines, 
concerned medicinal plants are thus of great importance. 
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Table 2: List of some of the important Antidiabetic plants with their family 
Name of plant Family Part used Acivity found 
Alangium lamarckii Alangiaceae Leaves Antidiabetic activity 
Albizia odoratissima Mimosaceae Bark Antidiabetic activity 
Axonopus compressus Poaceae Leaves Antidiabetic activity 
Acorus calamus Leguminosae Seeds Antidiabetic activity 
Aloe vera Araceae Radix Antidiabetic activity 
Azadirachta indica Meliaceae Leaves, seeds Antidiabetic activity 
Bauhinia forficate Fabaceae Leaves Antidiabetic activity 
Berberis vulgaris Berberidaceae Root Antidiabetic activity 
Brassssica juncea Cruciferae Seed Antidiabetic activity 
Beta vulgaris  Chenopodiaceae Root Antidiabetic activity 
Bixa orellana Bixaceae Leaves Antidiabetic activity 
Caesalpinia digyna Fabaceae Root Antidiabetic activity 
Catharanthus roseus Apocynaceae Leaf Antidiabetic activity 
Costus specious Costaceae Root Antidiabetic activity 
Curcuma longa Zingiberaceae Rhizome Antidiabetic activity 
Dendrobium chrysotoxum Orchidaceae Stem Antidiabetic activity 
Dolichandrone falcata Seem. Bignoniaceae  Leaf Antidiabetic activity 
Emblica officinalis Euphorbiaceae Fruit Antidiabetic activity 
Eucommia ulmoides Oliv.  Eucommiaceae  Leaf Antidiabetic activity 
Eugenia jambolona Myrtaceae Seeds Antidiabetic activity 
Ficus bengalensis Moraceae Root, Stem Antidiabetic activity 
Ficus carica Moraceae Leaves Antidiabetic activity 
Flacourtia jangomas Raeusch  Flacourtiaceae  Leaves Antidiabetic activity 
Gardenia taitensis A. P. de Candolle  Rubiaceae  Leaves Antidiabetic activity 
Gymnema Sylvestre Asclepiadaceae Whole plant  Antidiabetic activity 
Holoptelea integrifolia (Roxb.) Ulmaceae  Stem Antidiabetic activity 
Hypericum perforatum L.  Hypericaceae  Leaves Antidiabetic activity 
Hedychium spicatum Zingiberaceae Rhizome Antidiabetic activity 
Juglans regia L.  Juglandaceae  Leaves Antidiabetic activity 
Juniperus chinensis Cupressaceae Fruit Antidiabetic activity 
Lagerstroemia speciosa (L.) Pers  Lythraceae  Leaves Antidiabetic activity 
Linum usitatisumum Linaceae Seeds Antidiabetic activity 
Memecylon umbellatum Burm.F  Melastomataceae  Leaves Antidiabetic activity 
Mimosa pudica L.  Mimosaceae  Leaves Antidiabetic activity 
Murraya koenigii Rutaceae Leaves Antidiabetic activity 
Myrcia uniflora  Myricaceae  Leaves Antidiabetic activity 
Ocimum sanctum Lamiaceae Leaves Antidiabetic acitvity 
Olea europaea  Oleaceae  Leaves Antidiabetic acivity 
Paeonia lactiflora Paeoniaceae Roots Antidiabetic activity 
Raphanus sativus Brassicaceae Root Antidiabetic activity 
Solanum trilobatum  Solanaceae  Leaves Antidiabetic activity 
Sonneratia alba  Sonneratiaceae  Leaves Antidiabetic activity 
Spinacia oleracea  Chenopodiaceae  Leaves Antidiabetic activity 
Symplocos cochinchinensis  Symplocaceae Leaves Antidiabetic activity 
Tridax procumbens Asteraceae Whole plant Antidiabetic activity 
Urtica dioica  Urticaceae  Leaves Antidiabetic activity 
Withania somnifera  Solanaceae  Root Antidiabetic activity 
Zizyphus sativa  Rhamnaceae  Leaves Antidiabetic activity 
 
Conclusion 
The global costs of diabetes and its consequences are large 
and will substantially increase by 2030. Even if countries 
meet the international targets, the global economic burden 
will not decrease. Herbal Drugs can play an effective role in 
lowering the global economic burden as these are cost 
effective and by implication of recent advanced technologies 
like Nanotechnology can increase the higher therapeutic 
index of Herbal Drugs. 
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